This study was to investigate on the coexistence of diabetes mellitus type 2 and BPH and to correlate among these conditions could exist. Furthermore, the relationship between benign prostatic hyperplasia and serum insulin-like growth factor-1 levels in those patients, by examination the correlation of prostate size with serum IGF1, age, prostatic specific antigen levels in patient groups are to be compared to non diabetic age-matched controls. Fasting blood specimens from sixty type 2 diabetic males, 33 of them had normal prostatic specific antigen levels (<4 ng/ml) and enlarged prostate according to digital rectal examination and trans abdominal ultrasound with lower urinary tract symptoms as a result of benign prostatic hyperplasia (BPH), as group a-(with a mean age of 62.4±5.1 years) and the rest (27) of them without BPH, as group b-(had a mean age of 56 ±5.2 years), who were attending the Al-Sader Teaching Hospital in Al-Najaf/Iraq, besides nineteen apparently healthy control males. Serum insulin-like growth factor-1, insulin, prostate specific antigen (PSA) concentrations were measured by a ELISA kits. The mean serum IGF-1 levels were significantly elevated in type 2 diabetic patients with BPH compared to diabetics without BPH (145 ± 41.1 and 88 ± 41.1 ng/ml respectively), while control group had a mean serum IGF-1 levels of 75±19.1ng/ml, Whereas, PSA values (2.37±0.98) were significantly elevated in diabetics with BPH compared to the other groups (0.7 ± 0.3 and 0.9± 0.2). A significant correlation was detected between prostatic size & IGF-1 levels in diabetics with BPH (r= 0.554, p˂ 0.001), which was undetectable in diabetics without BPH (r=0.256 , P=0.197). Our findings suggest that insulin-like growth factor-1 may have an etiologic role in BPH development in type 2 diabetic patient whose duration of diabetes less than 7 years.